InvestSMART

Nuchev Limited (ASX:NUC)

ALERT: Price-sensitive ASX Announcement for NUC
Current share price for NUC : $0.085 -0.075 (-46.88%)+
Announcement
Release
28 Aug 2025 9:53AM
Price at Release
$0.160
Full Release
download
Summary
Nuchev Limited (NUC) delivered its FY25 Results and Business Update Presentation, outlining its strategic focus on the premium goat milk infant formula market in China and Australia. The company reported a significant revenue increase in Q3 FY24 compared to the previous year, driven by effective channel expansion and new product launches, including the Oli6® Stage 4 and Stage 1 Goat Infant Formula. Nuchev has made progress in diversifying its portfolio with increased investment in marketing, sales, and digital channels to capture growing demand in the cross-border e-commerce (CBEC) market. The management emphasized cost discipline, improved operational efficiencies, and a robust balance sheet. The presentation also highlighted the company's continued commitment to quality, safety, and innovation, with a focus on sustainable growth and strengthening its brand position in the premium segment. Key operational priorities for the next period include channel expansion, portfolio growth, and continued margin improvement.
Key Points
  • Nuchev Limited targets the premium goat milk infant formula market in China and Australia.
  • The company achieved strong revenue growth in Q3 FY24 year-on-year.
  • Channel expansion and new product launches, including Oli6® Stage 4 and Stage 1, contributed to performance.
  • Investment in marketing, sales, and digital channels is driving growth, especially in cross-border e-commerce.
  • Management is prioritizing cost control, operational efficiencies, and maintaining a solid balance sheet.
  • Ongoing commitment to product quality, safety, and innovation remains central to strategy.
  • Future focus areas include expanding distribution, growing the product portfolio, and improving profit margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.